Literature DB >> 7487406

Microvascular invasion in prostate cancer correlates with pathologic stage.

D R Salomao1, S D Graham, D G Bostwick.   

Abstract

OBJECTIVE: To determine the incidence of microvascular invasion in prostatic carcinoma and its correlation with other prognostic factors.
DESIGN: Evaluation of the frequency and extent of microvascular invasion by routine light microscopy in 210 whole-mounted radical prostatectomies with cancer.
RESULTS: Microvascular invasion was identified in 111 (53%) of 210 specimens. Focal microvascular invasion (involvement of fewer than three high-power fields) was present in 42 cases (20%); extensive microvascular invasion (involvement of three or more high-power fields) was present in 69 cases (33%). Capsular perforation was present in 43% and 62% of cases with focal and extensive microvascular invasion, respectively. Seminal vesical involvement was observed in 23% and 47% of cases with focal and extensive microvascular invasion, respectively. Lymph node metastases were only observed in cases with microvascular invasion and were present in 7% and 23% of cases with focal and extensive invasion, respectively. There was also a strong positive correlation of microvascular invasion with surgical margin status, Gleason score, and cancer volume. Tumors ranged in volume from 0.14 cc to 47.25 cc (mean, 9.09 cc), and the volume in cases without microvascular invasion was lower than in those with invasion (mean, 5.4 cc and 12.7 cc, respectively); also, the volume in cases with focal invasion was lower than in those with extensive invasion (mean, 9.4 cc and 16.1 cc, respectively).
CONCLUSIONS: Microvascular invasion in prostatic carcinoma correlates positively with virtually all measures of pathologic stage. Its presence should be reported in all prostate specimens according to the Cancer Committee of the College of Americans Pathologists.

Entities:  

Mesh:

Year:  1995        PMID: 7487406

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  8 in total

Review 1.  Histopathology reporting of prostate needle biopsies. 2005 update.

Authors:  Rodolfo Montironi; Remigio Vela Navarrete; Antonio Lopez-Beltran; Roberta Mazzucchelli; Gregor Mikuz; Aldo V Bono
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

2.  Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications.

Authors:  S R Potter; J I Epstein; A W Partin
Journal:  Rev Urol       Date:  2000

3.  A data-driven approach to prostate cancer detection from dynamic contrast enhanced MRI.

Authors:  Nandinee Fariah Haq; Piotr Kozlowski; Edward C Jones; Silvia D Chang; S Larry Goldenberg; Mehdi Moradi
Journal:  Comput Med Imaging Graph       Date:  2014-07-05       Impact factor: 4.790

Review 4.  Evaluating radical prostatectomy specimens: therapeutic and prognostic importance.

Authors:  D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

Review 5.  Prognostic significance of lymphovascular invasion in radical prostatectomy specimens.

Authors:  David S Yee; Shahrokh F Shariat; William T Lowrance; Alexandra C Maschino; Caroline J Savage; Angel M Cronin; Peter T Scardino; James A Eastham
Journal:  BJU Int       Date:  2010-11-02       Impact factor: 5.588

6.  Prostate cancer: epidemiology and screening.

Authors:  M K Brawer; E D Crawford; J Fowler; M S Lucia; F H Schröeder
Journal:  Rev Urol       Date:  2000

7.  Prognostic significance of lymphovascular space invasion in epithelial ovarian cancer.

Authors:  Ming Chen; Ying Jin; Yalan Bi; Yan Li; Ying Shan; Lingya Pan
Journal:  J Cancer       Date:  2015-02-27       Impact factor: 4.207

8.  Salvage radiotherapy after radical prostatectomy: outcomes and prognostic factors especially focusing on pathological findings.

Authors:  Satoko Hayashi; Keiji Hayashi; Ryo-ichi Yoshimura; Hitoshi Masuda; Kazunori Kihara; Hitoshi Shibuya
Journal:  J Radiat Res       Date:  2012-07-10       Impact factor: 2.724

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.